Contents

Highlights of This Issue 3089

SPECIAL FEATURES

3091 How to Train Your Biomarker
Douglas Yee
See article p. 3193

3094 Inhibition of the PI3K Pathway:
Hope We Can Believe in?
Michiel S. van der Heijden
and René Bernards

3100 Immunogenic Tumor Cell Death
for Optimal Anticancer Therapy:
The Calreticulin Exposure Pathway
Laurence Zitvogel, Oliver Kepp,
Laura Senovilla, Laurie Menger,
Nathalie Chaput, and Guido Kroemer

CCR Translations

3105 Drugs That Target the Stemness Pathways
Susan E. Bates

3106 Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways
Naoko Takebe and S. Percy Ivy

3113 Cancer Stem Cells and Self-renewal
Catherine Adell O’Brien, Antonija Kreso,
and Catriona H.M. Jamieson

3121 The Difficulty of Targeting Cancer Stem Cell Niches
Mark A. LaBarge

3130 Targeting Hedgehog—a Cancer Stem Cell Pathway
Akil A. Merchant and William Matsui

3141 Targeting Notch to Target Cancer Stem Cells
Antonio Pannuti, Kimberly Foreman,
Paola Rizzo, Clodia Osipo, Todd Golde,
Barbara Osborne, and Lucio Miele

3153 Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?
Fumi Takahashi-Yanaga and Michael Kahn

HUMAN CANCER BIOLOGY

3163 Molecular Diagnosis of Activating EGFR Mutations in Non–Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis
Akihiko Kawahara, Chizuko Yamamoto,
Kazutaka Nakashima, Koichi Azuma,
Satoshi Hattori, Masaki Kashihara,
Hisamichi Aizawa, Yuji Basaki,
Michihiko Kuwano, Masayoshi Kage,
Tetsuya Mitsudomi, and Mayumi Ono

3171 Aurora Kinase A Promotes Ovarian Tumorigenesis through Dysregulation of the Cell Cycle and Suppression of BRCA2
Gong Yang, Lin Zhang, Fan Yang,
Xiaodong Guo, Kathy Qi Cai,
Xue (Sherry) Xiao, Huamin Wang,
Subrata Sen, Mien-Chie Hung,
Gordon B. Mills, Sandy Chang,
Ash A. Multani, Imelda Mercado-Uribe,
and Jinsong Liu

CANCER THERAPY: PRECLINICAL

3182 FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma
Qing Liu, Lapo Alinari, Ching-Shih Chen,
Fengting Yan, James T. Dalton,
Rosa Lapalombella, Xiaoli Zhang,
Rajeswaran Mani, Teresa Lin, John C. Byrd,
Robert A. Baiocchi, and Natarajan Muthusamy

3193 Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
Todd M. Pitts, Aik Choon Tan,
Gillian N. Kulikowski, John J. Tentler,
Amy M. Brown, Sara A. Flanigan,
Stephen Leong, Christopher D. Coldren,
Fred R. Hirsch, Mairelle Varela-Garcia,
Christopher Korch, and S. Gail Eckhardt
See commentary p. 3091
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3260</td>
<td>Phase II Clinical and Pharmacokinetic Study of Plitidepsin 3-Hour Infusion Every Two Weeks Alone or with Dexamethasone in Relapsed and Refractory Multiple Myeloma</td>
<td>María Victoria Mateos, María Teresa Cibeira, Paul G. Richardson, Felipe Prospér, Albert Oriol, Javier de la Rubia, Juan José Lahuerta, Sergio Syljdergemajin, Claudia Corrado, Harald Singer, Constantine S. Mitsiades, Kenneth C. Anderson, Joan Bladé, and Jesús San Miguel</td>
</tr>
<tr>
<td>3270</td>
<td>Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants</td>
<td>Barbara L. Andersen, Lisa M. Thornton, Charles L. Shapiro, William B. Farrar, Bethany L. Mundy, Hae-Chung Yang, and William E. Carson III</td>
</tr>
<tr>
<td>3279</td>
<td>AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial</td>
<td>Per-Uno Malmström, Angelica S.I. Loskog, Camilla A. Lindqvist, Sara M. Mangsbo, Moa Fransson, Alkwim Wanders, Truls Gårdmark, and Thomas H. Tötterman</td>
</tr>
<tr>
<td>3288</td>
<td>Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients</td>
<td>Delphine Kérob, Raphael Porcher, Olivier Vérola, Stephane Dalle, Eve Maubec, François Aubin, Michel D’Incan, Isaak Bodokh, Serge Boulinguez, Isabelle Madelaine-Chambrin, Anne Mathieu-Boue, Jean-Marie Servant, Eric de Kerviler, Anne Janin, Fabien Calvo, Florence Pedeutour, and Celeste Lebbe</td>
</tr>
<tr>
<td>3294</td>
<td>Molecular Imaging of N-linked Glycosylation Suggests Glycan Biosynthesis Is a Novel Target for Cancer Therapy</td>
<td>Joseph N. Contessa, Mahaveer S. Bhojani, Hudson H. Freeze, Brian D. Ross, Alnawaz Rehemtulla, and Theodore S. Lawrence</td>
</tr>
<tr>
<td>3300</td>
<td>Drug-Induced Vessel Remodeling in Bone Metastases as Assessed by Dynamic Contrast Enhanced Magnetic Resonance Imaging and Vessel Size Imaging: A Longitudinal In vivo Study</td>
<td>Tobias Bäuerle, Maximilian Merz, Dorde Komljenovic, Stefan Zwick, and Wolfhard Semmler</td>
</tr>
<tr>
<td>3305</td>
<td>Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC</td>
<td>Nita Amornsiripanitch, Shaolin Hong, Michael J. Campa, Michael M. Frank, Elizabeth B. Gottlin, and Edward F. Patz, Jr.</td>
</tr>
<tr>
<td>3313</td>
<td>A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam</td>
<td>Andrew J. Vickers, Angel M. Cronin, Monique J. Roobol, Caroline J. Savage, Mari Peltola, Kim Petterson, Peter T. Scardino, Fritz H. Schröder, and Hans Lilja</td>
</tr>
<tr>
<td>3320</td>
<td>HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth</td>
<td>Till Milde, Ina Oehme, Andrey Korshunov, Annette Kopp-Schneider, Marc Remke, Paul Northcott, Hedwig E. Deubzer, Marco Lodriní, Michael D. Taylor, Andreas von Deimling, Stefan Pfister, and Olaf Witt</td>
</tr>
<tr>
<td>3328</td>
<td>Overexpression of p73 as a Tissue Marker for High-Risk Gastritis</td>
<td>Gonzalo Carrasco, José Diaz, José R. Valbuena, Paulina Ibanez, Paz Rodriguez, Gabriela Araya, Carolina Rodriguez, Javiera Torres, Ignacio Duarte, Edmundo Aravena, Fernando Mena, Carlos Barrientos, and Alejandro H. Corvalan</td>
</tr>
<tr>
<td>3334</td>
<td>Imatinib Mesylate as a Preoperative Therapy in Dermatofibrosarcoma: Results of a Multicenter Phase II Study on 25 Patients</td>
<td>Delphine Kérob, Raphael Porcher, Olivier Vérola, Stephane Dalle, Eve Maubec, François Aubin, Michel D’Incan, Isaak Bodokh, Serge Boulinguez, Isabelle Madelaine-Chambrin, Anne Mathieu-Boue, Jean-Marie Servant, Eric de Kerviler, Anne Janin, Fabien Calvo, Florence Pedeutour, and Celeste Lebbe</td>
</tr>
</tbody>
</table>
ABOUT THE COVER

Early detection of gastric cancer requires risk assessment of premalignant conditions. The cover image shows a positive and negative representative immunostain of eight tissue markers (BRCA1, HSP90, EGFR, p73, STAT1, FHIT, p16INK4a and p53) and EBER-1 expression in tissue microarrays of early gastric cancer, nontumor adjacent mucosa, and chronic gastritis control cases, where p73 emerges and may have a potential role in the assessment of high-risk gastritis. Moreover, integration of these findings with histological features shows that overexpression of p73 is the most relevant finding. For further details, please see the article by Carrasco and colleagues on page 3253 of this issue.